Psoriasis affects approximately 2% of the UK population—over 1.4 million people—according to the Psoriasis Association. As a chronic, immune-mediated skin disorder characterised by well-demarcated, red, scaly plaques, psoriasis significantly impacts quality of life, mental health, and social functioning. The NHS emphasises a multifaceted management approach combining topical, phototherapy, systemic, and biological therapies to control symptoms and improve patient wellbeing.
Understanding Psoriasis: Pathophysiology and Clinical Features
Psoriasis results from accelerated skin cell proliferation driven by immune system dysregulation.
Pathogenesis:
- Genetic predisposition: Multiple susceptibility loci identified (e.g., PSORS1)
- Immune system activation: T-helper (Th1 and Th17) cell-mediated inflammation
- Cytokine network: Key roles for TNF-α, IL-17, IL-23
- Keratinocyte hyperproliferation: Plaque formation
- Environmental triggers: Infections, stress, medications, trauma (Koebner phenomenon)
Clinical Subtypes:
- Plaque Psoriasis (80-90%): Well-defined raised, red plaques with silvery scale, commonly on elbows, knees, scalp, lower back
- Guttate Psoriasis: Small, drop-like lesions often triggered by streptococcal infection
- Inverse (Flexural) Psoriasis: Smooth, red lesions in skin folds (axillae, groin)
- Pustular Psoriasis: Sterile pustules on erythematous base, can be localized (palms/soles) or generalized
- Erythrodermic Psoriasis: Rare severe form with widespread redness covering >90% of body surface
Nail Psoriasis: pitting, onycholysis, subungual hyperkeratosis, oil drop sign
Associated Comorbidities:
- Psoriatic arthritis (30% of patients)
- Metabolic syndrome (obesity, diabetes, dyslipidemia)
- Cardiovascular disease
- Depression and anxiety
- Inflammatory bowel disease
Diagnosis and Assessment
Diagnosis is primarily clinical, based on lesion morphology and distribution. The British Association of Dermatologists recommends:
Clinical Evaluation:
- Detailed history: onset, triggers, family history, impact on quality of life
- Full skin examination: morphology, severity (PASI score)
- Nail and joint examination for psoriatic arthritis
Differential Diagnosis:
- Eczema, tinea corporis, pityriasis rosea, seborrheic dermatitis
- Biopsy rarely needed unless atypical presentation
Assessment Tools:
- Psoriasis Area Severity Index (PASI)
- Dermatology Life Quality Index (DLQI)
- Body Surface Area (BSA)
- Physician Global Assessment (PGA)
Treatment Options
Therapy selection depends on severity, comorbidities, patient preference, and response history.
Topical Treatments (Mild-to-Moderate Psoriasis):
Emollients:
- Base for all topical regimens
- Maintain skin hydration
- Apply multiple times daily
Topical Corticosteroids:
- First-line anti-inflammatory agents
- Various potencies; limit duration of high-potency use
- Combination with vitamin D analogues improves efficacy
Vitamin D Analogues:
- Calcipotriol, calcitriol inhibit keratinocyte proliferation
- Often combined with corticosteroids
- Avoid on face and flexures due to irritation
Coal Tar & Anthralin:
- Slowing cell turnover and reducing scaling
- Less commonly used due to mess and irritation
Calcineurin Inhibitors:
- Tacrolimus, pimecrolimus for sensitive areas
- Off-label use, avoid long-term skin application
Phototherapy (Moderate-to-Severe Psoriasis):
Narrowband UVB (311 nm):
- First-line phototherapy option
- 2-3 sessions weekly until clearance
- Maintenance therapy as needed
Psoralen + UVA (PUVA):
- Effective for more severe disease
- Psoralen sensitizes skin to UVA
- Increased skin cancer risk with long-term use
Excimer Laser:
- Targeted UVB for localized plaques
- Minimizes exposure to surrounding skin
Systemic Treatments (Severe or Refractory Psoriasis):
Methotrexate:
- Antimetabolite reducing keratinocyte proliferation
- Weekly dosing with folic acid supplementation
- Monitor liver function and blood counts
Acitretin:
- Oral retinoid normalizing keratinocyte differentiation
- Teratogenic; strict contraception required
- Dose-related mucocutaneous side effects
Cyclosporine:
- Calcineurin inhibitor suppressing T-cell activation
- Rapid efficacy but nephrotoxicity limits long-term use
Apremilast:
- PDE4 inhibitor modulating inflammatory pathways
- Oral dosing; moderate efficacy
- Diarrhea and weight loss common side effects
Biologic Therapies (Targeted Treatment):
TNF-α Inhibitors:
- Adalimumab, etanercept, infliximab, certolizumab pegol
- Highly effective for skin and joint disease
- Monitor for infections and TB screening
IL-12/23 Inhibitors:
- Ustekinumab targeting p40 subunit
- Two-dose regimen every 12 weeks
- Good safety and efficacy profile
IL-17 Inhibitors:
- Secukinumab, ixekizumab, brodalumab
- Rapid onset of action; effective
- Monitor for mucocutaneous candidiasis
IL-23 Inhibitors:
- Guselkumab, tildrakizumab, risankizumab
- Longer dosing intervals (every 8-12 weeks)
- Excellent efficacy and safety
Comprehensive Management Strategies
Patient Education:
- Understand chronic nature and treatment goals
- Importance of adherence to therapy
- Identification of triggers and lifestyle adjustments
Psychological Support:
- Address depression, anxiety, and social stigma
- Consider CBT or support groups
Lifestyle Modifications:
- Smoking cessation reduces severity and comorbid risk
- Weight management improves treatment response
- Stress reduction techniques to prevent flares
Comorbidity Management:
- Regular cardiovascular risk assessment
- Screening for psoriatic arthritis in all patients
- Management of metabolic syndrome components
Monitoring and Follow-Up:
- Assess treatment response (PASI, DLQI) every 12-16 weeks
- Monitor laboratory parameters for systemic agents
- Adjust therapy based on efficacy, side effects, and patient preferences
Future Directions in Psoriasis Care
Emerging Treatments:
- Novel small molecules targeting JAK-STAT pathway
- Bimekizumab: dual IL-17A/F inhibitor
- Personalized medicine based on genetic profiling
Research Areas:
- Role of microbiome in psoriasis pathogenesis
- Biomarkers predicting treatment response
- Long-term safety of biologic therapies
Conclusion
Psoriasis is a chronic, immune-mediated skin condition requiring a multifaceted treatment approach tailored to disease severity and patient needs. Advances in targeted therapies have revolutionized care, offering high efficacy and improved quality of life. Thorough assessment, patient education, and regular monitoring are essential for optimal management.
Combining topical, phototherapy, systemic, and biologic treatments with lifestyle modifications and psychological support enables effective control of skin disease and comorbidities. Collaboration between dermatologists, primary care physicians, and multidisciplinary teams ensures comprehensive care. For reliable information and support, patients can access resources from the Psoriasis Association and the NHS.
Remember that psoriasis management is lifelong, and treatment goals should focus on patient-centred outcomes: minimizing symptoms, optimizing function, and enhancing overall wellbeing.
